TuisARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
Vorige sluiting
$11,91
Dagwisseling
$12,05 - $12,93
Jaarwisseling
$8,04 - $42,42
Markkapitalisasie
346,87 m USD
Gemiddelde volume
445,45 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 29,38 m | -22,70% |
Bedryfskoste | 11,32 m | -23,81% |
Netto inkomste | -14,08 m | 47,51% |
Netto winsgrens | -47,91 | 32,09% |
Wins per aandeel | -0,52 | 48,00% |
EBITDA | -16,02 m | 45,69% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 216,95 m | -24,77% |
Totale bates | 331,78 m | -20,79% |
Totale aanspreeklikheid | 98,03 m | -36,71% |
Totale ekwiteit | 233,76 m | — |
Uitstaande aandele | 27,12 m | — |
Prys om te bespreek | 1,38 | — |
Opbrengs op bates | -12,45% | — |
Opbrengs op kapitaal | -15,41% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -14,08 m | 47,51% |
Kontant van bedrywe | -35,14 m | -532,32% |
Kontant van beleggings | -137,00 k | 42,92% |
Kontant van finansiering | 15,20 m | 594,47% |
Netto kontantverandering | -20,08 m | -456,39% |
Beskikbare kontantvloei | -12,28 m | -137,89% |
Meer oor
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Gestig
2013
Webwerf
Werknemers
175
